# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
The solution, which includes the VENTANA DP 200 slide scanner, Roche's digital pathology workflow software and a display,...
– The study met its primary endpoint of overall survival with a 41% reduction in the risk of death in people with relapsed or r...
– Priority Review recognizes the best-in-class potential of the inavolisib-based regimen for patients in urgent need of new t...
Renewed partnership combines best in class engineering capabilities with cutting edge science to accelerate the availability ...
– The designation is based on Phase III INAVO120 results, showing the inavolisib-based regimen more than doubled progression-fr...
Over 24 weeks, a once-weekly subcutaneous injection of CT-388 achieved a clinically meaningful and statistically significant ...
Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated nea...
Columvi, in combination with chemotherapy, demonstrated a statistically significant improvement in overall survival for peopl...
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2.1 Patients with HER2-low s...